Hesperetin-Enhanced Metformin to Alleviate Cognitive Impairment via Gut–Brain Axis in Type 2 Diabetes Rats
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26051923 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Danyang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian 116024, China. Hauptthemen laut MEDLINE: Hesperidin, Metformin, Cognitive Dysfunction, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yunnan Talent Support Plan for Industrial Innovation Talents, Major Science and Technology Projects in Yunnan Province, Academician (Expert) Workstation Construction Project of Yunnan Province, Natural Science Foundation of Hebei Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes constitutes a risk factor for cognitive impairment, whereas insulin resistance serves as the shared pathogenesis underlying both diabetes and cognitive decline. The use of metformin for treating cognitive impairment remains controversial. The present study found that hesperetin, a flavanone derived from citrus peel, enhanced metformin’s efficacy in reducing blood sugar levels, improving insulin sensitivity, and ameliorating cognitive impairment in diabetic rats. Additionally, it reduced the required dosage of metformin to one-third of its conventional dose. Transcriptome analysis and 16S rRNA sequencing revealed that the activation of insulin and cyclic-adenosine monophosphate response element binding protein (CREB)/brain-derived neurotrophic factor (BDNF) pathways benefited from the regulation of gut microbiota and the promotion of short-chain fatty acid (SCFA) producers such as Romboutsia. Furthermore, this study demonstrated that hesperetin supplementation counteracted the upregulation of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a pathological factor of Alzheimer’s disease (AD) that was induced by metformin. Our findings reveal that hesperetin can be used in supplementary treatment for cognitive impairment associated with diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian 116024, China.
- Dianxi Research Institute, Dalian University of Technology, Baoshan 678000, China.
- School of Ocean Science and Technology, Dalian University of Technology, Panjin 124221, China.
ORCID-Profile: Yan Xing, Yongming Bao, Yuesheng Dong
Förderung
- Yunnan Talent Support Plan for Industrial Innovation Talents, Major Science and Technology Projects in Yunnan Province
- Academician (Expert) Workstation Construction Project of Yunnan Province
- Natural Science Foundation of Hebei Province
Zitieren
APA
Zhang, D., He, X., Wang, Y., Wang, X., Han, X., Liu, H., Xing, Y., Jiang, B., Xiu, Z., Bao, Y., & Dong, Y. (2025). Hesperetin-Enhanced Metformin to Alleviate Cognitive Impairment via Gut–Brain Axis in Type 2 Diabetes Rats. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26051923
Vancouver
Zhang D, He X, Wang Y, Wang X, Han X, Liu H, et al. Hesperetin-Enhanced Metformin to Alleviate Cognitive Impairment via Gut–Brain Axis in Type 2 Diabetes Rats. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26051923
BibTeX
@article{Zhang2025,
author = {Zhang, Danyang and He, Xiaoshi and Wang, Yinbo and Wang, Xiaoyu and Han, Xiao and Liu, Haodong and Xing, Yan and Jiang, Bo and Xiu, Zhilong and Bao, Yongming and Dong, Yuesheng},
title = {Hesperetin-Enhanced Metformin to Alleviate Cognitive Impairment via Gut–Brain Axis in Type 2 Diabetes Rats},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26051923}
}
EUVIMED